Alterations in cardiac energy metabolism contribute to the severity of heart failure. However,
the energy metabolic changes that occur in heart failure are complex and are dependent not …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …

Cardiomyocytes exit the cell cycle and become terminally differentiated soon after birth.
Therefore, in the adult heart, instead of an increase in cardiomyocyte number, individual …

Background: Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin
Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be …

Ketone body metabolism is a central node in physiological homeostasis. In this review, we
discuss how ketones serve discrete fine-tuning metabolic roles that optimize organ and …

Background: Myocardial utilization of 3-hydroxybutyrate (3-OHB) is increased in patients
with heart failure and reduced ejection fraction (HFrEF). However, the cardiovascular effects …

Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …

The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%),
hospitalization for heart failure (35%), and death from any cause (32%) observed in the …

The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a
metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all …

While metabolic reprogramming of cancer cells has long been considered from the
standpoint of how and why cancer cells preferentially utilize glucose via aerobic glycolysis …